
Tanya Dorff, MD, City of Hope Comprehensive Cancer Center
Advertisement
Articles by Tanya Dorff, MD, City of Hope Comprehensive Cancer Center













Tanya Dorff, MD, assistant professor of Clinical Medicine, Keck Medicine of University of Southern California, discusses the role of chemotherapy in patients with metastatic castration-resistant prostate cancer and pivotal clinical trials that have explored this.
Advertisement
Latest Updated Articles
Dr. Dorff on Role of Chemotherapy in mCRPCPublished: October 6th 2016 | Updated:
FDA Approved Agents for Non-Metastatic CRPCPublished: July 9th 2020 | Updated:
Conventional Versus PSMA Imaging in Prostate CancerPublished: July 9th 2020 | Updated:
The CARD and PROfound Trials for Metastatic CRPCPublished: July 9th 2020 | Updated:
Emerging Therapies for Advanced Prostate CancerPublished: July 9th 2020 | Updated:
Data for Metastatic Castration-Sensitive Prostate CancerPublished: July 9th 2020 | Updated:
Advertisement
Advertisement
Trending on OncLive
1
Lurbinectedin-Based Triplet Shows Clinical Benefit in Advanced Soft Tissue Sarcoma
2
Ultra-Sensitive ctDNA and CSF Liquid Biopsy May Refine Monitoring and Adaptive Trial Designs in Metastatic Breast Cancer
3
Anti–Gremlin-1 Therapy Plus Chemo Makes Waves in GI Malignancies
4
Nuvisertib Yields Strong Safety, Promising Efficacy in R/R Myelofibrosis
5

